ArticleJournal of neuro-oncology2025
Temporospatial tumor dynamic changes in glioblastoma during radiotherapy.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiotherapy for glioma in the AI era: current applications and future prospects.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlioblastoma (GBM) management post maximal-safe resection consists of concurrent chemoradiation (CRT) and adjuvant chemotherapy. MRIs are historically performed post-operatively and/or at treatment planning. Continuous interfractional changes during CRT have not been adequately characterized. MR-guided radiation therapy (MRgRT) allows for detailed imaging of tumor volumes during the course of treatment. This is a preliminary initial report evaluating temporal and spatial changes that occur in GBM, in order to model tumor dynamics.
methodsFive GBM patients enrolled onto an institutional biorepository registry underwent treatment with our 0.35T MRgRT workflow. Target volumes were delineated based on T2/FLAIR (GTV_46Gy) and T1 gadolinium-enhanced MR (GTV_14Gy) sequences. Weekly post-contrast MRIs were performed during CRT with the 0.35T magnet to monitor target volume dynamics.
resultsThirty-five MR scans were evaluated. The median time from surgery to CRT was 32 days (range: 28-40), with a median of 13 days (range: 12-14) from simulation to CRT. We found median volume reductions of 40.0% (range: 8.3-86.5%), and 37.1% (range: 15.0-67.5%) for GTV_46Gy and GTV_14Gy, respectively. The bulk of these changes occurred early, within the first 3 weeks of the 6-week treatment, with significant reductions observed between baseline and week 1 -32.6% for GTV_46Gy and 17.9% for GTV_14Gy. Separately, statistically significant volume reductions for the cavity volume (F = 59.43, p < 0.05) were observed. Compared to baseline, centroid migrations of the target volumes were also noted: the median GTV_46Gy centroid migration was 7.4 mm (range: 2.0-10.8 mm) and the median GTV_14Gy centroid migration was 3.6 mm (range: 1.3-8.8 mm).
conclusionsOur pilot study suggests that weekly MRgRT imaging for GBM patients undergoing long course CRT reveals significant GTV reductions and centroid migrations, especially during the first 3 weeks of treatment. A more detailed understanding of which patients are at highest risk for tumor change and migration is needed to best apply these imaging parameters to clinical practice.
Indexed as
Identifiers
40299247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.